Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304)

Uterine Cervical Cancer Clinical Trial

— KETOCOL-1304  

Official title:

Paracetamol With or Without Ketoprofen in the Management of Pain During Hospitalisation and at Home for Patients Receiving Brachytherapy: Phase-2 Randomized Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02439034
• Other study ID #: KETOCOL-1304
• Status: Recruiting
• Phase: Phase 2
• First received: April 30, 2015
• Last updated: July 27, 2016
• Start date: February 2015
• Est. completion date: March 2018

Study information

• Verified date: July 2016
• Source: Centre Oscar Lambret
• Contact: Danièle LEFEBVRE-KUNTZ, MD
• Phone: +33 3 20 29 59 89
• Email: d-lefebvre[@]o-lambret.fr
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santéFrance: Committee for the Protection of Personnes
• Study type: Interventional

Clinical Trial Summary

The results of the study will permit to set up a standardized and validated procedure of pain management authorizing medical and paramedical staff of brachytherapy department to handle pain and in this way to improve the quality of life of the patients.

Description:

• Selection criteria validation

• Patient information and collection of a signed informed consent

• Randomization

• Completion of HADS questionnaire

• Day 1 = Begin of analgesic treatment / brachytherapy

• T-30= 30 minutes before the operative procedure, IV administration of the analgesic treatment (Arm A or B) by the anesthetist

• T0= end of the operative procedure under general anesthesia

• T4, T8, and T12 = 4, 8 and 12 hours after T0: evaluation of pain level. If pain level ≥ 4:

1. paracetamol-codeine (Arms A and B) and continuation of ketoprofen (Arm B). Then, if persistence of pain :

2. paracetamol and morphine (Arms A and B)

• Day 2 to Day 30: At home or during hospital stay:

Pain assessment twice a day by the patient until absence of pain during 2 consecutive days

• Day 3 and Day 15: Pain assessment or phone interview by the algologist of the investigation center ; completion of a HADS questionnaire on Day 3

• Day 30= End of study: Pain assessment by the algologist of the investigation center and HADS questionnaire

In any case, pain assessment must be done until absence of pain during 2 consecutive days

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: March 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patient with a uterine cervical cancer or an upper aero-digestive tract cancer

• Age = 18 years and = 75 years

• Patient who are eligible for brachytherapy treatment associated with or without hospital stay

• With operative procedure under general anesthesia to set up the material needed for brachytherapy

• Performance status = 2

• Creatinine Clearance = 60 ml/min using Cockcroft equation

• No coagulation disorder or anticoagulation therapy at curative dose

• Registered with a social security system

• Patient having dated and signed an informed consent form before initiation of any study procedures

Exclusion Criteria:

• Respiratory pathology (SpO2< 70 %)

• Severe undernutrition

• Previous hypersensitivity reactions such as bronchospasm, asthma, rhinitis, hives or other allergic reaction to ketoprofen, to acetylsalicylic acid, or other NSAIDs

• Previous hemorrhage or gastrointestinal perforation during a previous treatment with NSAID

• Gastrointestinal hemorrhage , cerebrovascular hemorrhage or other evolutive hemorrhage

• Evolutive peptic ulcer, previous peptic ulcer or recurring hemorrhage (2 or more distinct episodes of hemorrhage or ulcer objectified)

• Liver insufficiency

• Severe renal insufficiency

• Severe heart failure

• Treatment with another NSAID, including selective cyclooxygenase-2 inhibitors

• Intolerance or hypersensitivity to one of the treatments or excipients

• Inability to swallow

• Pregnant or breastfeeding woman

• Patient under tutorship or guardianship

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Head and Neck Neoplasms
• Upper Aerodigestive Tract Neoplasms
• Uterine Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• Paracetamol
Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
• Ketoprofen
Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.

Locations

Country	Name	City	State
France	Centre Oscar Lambret	Lille

Sponsors (2)

Lead Sponsor	Collaborator
Centre Oscar Lambret	SANTELYS

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Level of immediate post-operative pain	Immediate post-operative pain will be assessed on a scale from 0 to 10. Experimental treatment will be considered as a success if the level of pain is < 4, 4 hours after the surgical operation.	Day 1	No
Secondary	Level of pain linked to the operative procedure during brachytherapy and at home	Assessment of the pain level at 8, 12 hours after the operative procedure, then twice a day during hospital stay or at home until the absence of pain during 2 consecutive days. This level will also be measured at days 3, 15 and 30 at hospital or during a phone interview (Days 3 and 15) and by the algologist of the investigation center on Day 30.	Day 1 (8, 12 hours), Days 3, 15 and 30	No
Secondary	Tolerance of the analgesic treatment	assessment based on NCI-CTCAE v4.0	30 days	No
Secondary	Assessment of anxiety before, during and after brachytherapy by completing the HADS questionnaire		inclusion, Days 3 and 30	No